PepGen (PEPG) vs Tiziana Life Sciences (TLSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Tiziana Life Sciences (TLSA) has outperformed PepGen (PEPG) over the past year, losing 44.1% versus a loss of 47.9%. PepGen is the larger company by market cap ($181.2 million vs $151.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PEPG | TLSA |
|---|---|---|
| Share price | $2.62 | $1.19 |
| Market cap | $181.22M | $151.44M |
| 1-day change | +10.08% | +5.31% |
| YTD return | -59.75% | -20.13% |
| 1-year return | -47.91% | -44.13% |
| 5-year return | — | -21.19% |
| EPS (TTM) | $-1.01 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.80 | $2.25 |
| 52-week low | $1.31 | $0.76 |
| Distance from 52-week high | -66.41% | -47.11% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +288.93% | +572.27% |
| Average volume | 923.99K | 720.16K |
| Shares outstanding | 69.17M | 127.26M |
| Employees | 57 | 10 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Healthcare · Biotechnology · 57 employees
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Healthcare · Biotechnology · 10 employees
PEPG vs TLSA FAQ
Which is bigger, PepGen or Tiziana Life Sciences?
PepGen (PEPG) is larger, with a market capitalization of $181.22M compared with $151.44M for Tiziana Life Sciences (TLSA).
Which stock has performed better over the past year, PEPG or TLSA?
TLSA returned -44.13% over the past 12 months, compared with -47.91% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Are PepGen and Tiziana Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.